Integrase inhibitors: Why do we need a new drug class for HIV therapy?

European Journal of Medical Research

Volumn 14, Issue SUPPL.3, 2009, Pages 1-3

  Rockstroh, Jürgen Kurt ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE INHIBITOR;

ANTIVIRAL RESISTANCE; DRUG DESIGN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS;

EID: 77951225696     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-14-S3-1     Document Type: Article

References (12)

1. Rapidly ageing HIV epidemic among men who have sex with men in Australia. Murray JM, McDonald AM, Law MG, Sex Health 2009 6 83 86 10.1071/SH08063 19254497
2. Raltegravir: molecular basis of its mechanism of action. Mouscadet JF, Tchertanov L, Eur J Med Res 2009 14 Suppl III 5 16 19959411
3. Drug-drug interactions with raltegravir. Burger D, Eur J Med Res 2009 14 Suppl III 17 21 19959412
4. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-nave patients with HIV-1 infection: results of a 48-week controlled study. Markowitz M, Nguyen BY, Gotuzzo E, et al. J Acquir Immune Defic Syndr 2007 46 125 10.1097/QAI. 0b013e318157131c 17721395 (Pubitemid 47482607)
5. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-nave patients with HIV-1 infection. Markowitz M, Nguyen BY, Gotuzzo E, et al. J Acquir Immune Defic Syndr 2009 52 350 356 10.1097/QAI.0b013e3181b064b0 19648823
6. Raltegravir in treatment-naive patients. Cossarini F, Castagna A, Lazzarin A, Eur J Med Res 2009 14 Suppl III 22 29 19959413
7. Raltegravir with optimized background therapy for resistant HIV-1 infection. Steigbigel RT, Cooper DA, Kumar PN, BENCHMRK Study Teams, et al. N Engl J Med 2008 359 339 354 10.1056/NEJMoa0708975 18650512
8. ANRS 139 TRIO Trial group High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected withmultidrug-resistant HIV: results of the ANRS 139 TRIO trial. TRIO, Yazdanpanah Y, Fagard C, Descamps D, et al. Clin Infect Dis 2009 49 1441 9 10.1086/630210 19814627
9. The use of integrase inhibitors in treatment-experienced patients. Gatell J, Eur J Med Res 2009 14 Suppl III 30 35 19959414
10. HIV/HCV coinfection: Which role can new antiretrovirals such as integrase inhibitors play? Vogel M, Nelson M, Eur J Med Res 2009 14 Suppl III 36 42 19959415
11. Raltegravir use in special populations. Johnson M, Eur J Med Res 2009 14 Suppl III 43 46 19959416
12. HIV Resistance to Raltegravir. Clavel F, Eur J Med Res 2009 14 Suppl III 47 54 19959417